Biocon unit plans 15% stake sale to Serum Institute for access to vaccines

The deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the initial years, the companies said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3CpShC7
via IFTTT